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Introduction. There are controversies over the long-term persis-
tence of post vaccination immunity to hepatitis B and the need for 
booster doses of the vaccine. The aim of this study was to verify 
antibody levels of antibody against hepatitis B virus surface anti-
gen (anti-HBs) in children aged 1 to 15 years who received vacci-
nation against hepatitis B in the central province of Iran, Semnan.
Materials and methods. We performed a seroepidemiological 
survey (n = 210) of anti-HBs in 2011 in the central province of 
Iran, Semnan using enzyme-linked immunosorbent assay (ELISA). 
The levels of anti-HBs < 10 mIU/mL were considered to be nega-
tive and samples showing an anti-HBs titer ≥  10 mIU/mL was 
considered protective.
Results. Protective antibody levels were detected in 88% of the 
children less than 5 year after vaccination, decreased to 78% 
between 5 to 10 years after vaccination, and further declined to 
74% in 10 years after vaccination, respectively.
Conclusion. The vaccination program has been proven effec-
tive in Semnan and immunological protection against hepatitis B 
infection was found in the majority of children even more than 10 
years after being vaccinated. 
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Summary
Introduction
The vaccine against hepatitis B virus (HBV) is included 
in the routine immunization schedule for children in 
most countries with the ultimate goal of reducing the 
prevalence of chronic hepatitis B carriers, as well as pre-
venting the occurrence of acute hepatitis B [1]. Although 
long-term reduction of chronic HBV after hepatitis B 
vaccination has been reported  [2], decreasing the lev-
els of antibody against hepatitis B surface antigen (anti-
HBs) over the time can be alarming [3].
Hepatitis B virus (HBV) prevalence has decreased dra-
matically in Iranian population since 1993 when the 
mass vaccination program was started. The geographic 
distribution of HBV infection in Iran showed hetero-
geneous patterns of HBV prevalence from the highest 
prevalence rates of more than 3% in northeastern region 
of our country to less than 2% in central and western 
regions of Iran [4]. 
Several hundred million doses of plasma-derived HB 
vaccines are produced in the Republic of Korea, China, 
Vietnam, Myanmar, India, Indonesia, Iran and Mongo-
lia [5, 6]. Engerix-B® (SmithKline Beecham, 1992) and 
Recombivax HB® (Merck & Co.) are considered as the 
two major yeast-derived hepatitis B vaccines that are li-
censed in most countries [5].
There are controversies over the long-term persistence 
of post vaccination immunity to HBV and the need for 
booster doses of the vaccine [7]. 
The aim of this study was to verify antibody levels of an-
ti-HBs antibodies in children aged 1 to 15 years who re-
ceived vaccination against HBV in accordance with the 
standard method in the central province of Iran, Semnan.
Materials and methods
In this cross-sectional study, all children between ages of 
1 and 15 years residing in Semnan, Iran in Amiralmoe-
menin hospital were tested for anti-HBs during 2009.
Informed consent was obtained from all children and/
or their parents or guardians who agreed to participate 
in the study. The questionnaire was completed about the 
child’s general data (e.g., family history of contact with 
HBV and knowledge about the possibility for the child 
to have any immunosuppressive disease, such as HIV, 
type 1 diabetes mellitus, or chronic renal failure).
We included immunocompetent participants without 
history of previous HBV infection.The participants were 
excluded from the study on the basis of
the following criteria: (a) were not screened for serologic 
markers of HBV infection (HBsAg) before vaccination; 
(b) born to HBsAg carrier mothers; (c) had predisposing 
factors for any immunosuppressive disease such as HIV 
positive.
After blood sample collections, plasma samples were 
collected and tested for anti-HBs using enzyme-linked 
immunosorbent assay (ELISA)(Delaware Biotech Inc. 
M. Rezaei et al.
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Dover, DE, USA) following the manufacturer’s proto-
col. 
The antigen and antibody formed a sandwich complex 
with the conjugated antibodies with the peroxidase 
(horseradish peroxidase) and the enzymatic activity was 
detected with the specific chromogen/substrate 3,3’,5,5’ 
-tetramethylbenzidine (TMB). 
The TMB levels were quantified at 450 nm and the 
concentrations of the anti-HBs were determined on the 
standard curve. The levels of anti-HBs <  10 mIU/mL 
were considered to be negative and samples showing 
an anti-HBs titer ≥ 10 mIU/mL was considered protec-
tive [1].
The Chi-square test and Fisher’s exact test were used 
with the SPSS 16 Package program (Chicago, IL, USA). 
Data were presented as mean ± SD or, when indicated, 
as an absolute number and percentage. Student’s t-test 
was used for statistical analysis to compare the means 
between the two groups.
Results
A total of 210 children were participated in this study. 
Totally, 67 cases (32%) were under 5 years, 67 (32%) 
were between 5 to 9 years old and 76 (36%) were more 
than 10 years. The male to female ratio was 1. Distribu-
tion of anti-HBs levels according to sex, age and dura-
tion after vaccination are shown in Table 1. Eighty four 
cases (80%) in the female group and 82 cases (78%) in 
the male group had protective levels of anti-HBs > 10 
mIU/mL, with no statistically significant difference in 
anti-HBs positivity and genders (p = 0.735). Anti-HBs 
positivity was seen in 87% of cases less than 5 years, 
81% of cases between 5 and 10 years and 71% of cases 
more than 10 years.
Protective antibody levels were detected in 88% of the 
children less than 5 year after vaccination, decreased to 
78% between 5 to 10 years after vaccination, and further 
declined to 74% in 10 years after vaccination, respec-
tively.
Discussion
The immunity derived from the HBV vaccine was as-
sessed by measuring the antibody in 210 children who 
were vaccinated in a routine vaccination program in cen-
tral province of Iran, Semnan.
In our study, among 210 cases, 166 children (79%) had 
antibodies levels ≥ 10 mIU/mL. Protective antibody lev-
els were detected in 88% of the children less than 5 year 
after vaccination, 78% in cases between 5 to 10 years 
after vaccination, and 74% in cases at 10 years after vac-
cination. Generally, 3-30% of vaccinated individuals 
lost their protective anti-HBs titres five years after the 
hepatitis B vaccination [8]. Long-term follow-up studies 
demonstrated that antibodies might become negative in 
15-50% among the vaccine responders within 5 to 10 
years [9, 10].
According to several studies among healthy children 
who had received a complete hepatitis B immunization 
program, the protective titer of anti-HBs antibody > 5 
years after the last dose were seen in 50-100% of indi-
viduals [7, 11-13]. It has been reported that the variabil-
ity in the anti-HBs antibody might be due to is the type 
of vaccine used, the amount of antigen delivered and the 
population immunized [14-17].
The HBV vaccination started in infants in two provinces 
(Zanjan and Semnan) in 1989, and since 1993 the vac-
cination was introduced in the expanded program on 
immunization in Iran. After implementation of HBV 
vaccination in our country, the coverage has reached 
an appropriate level 94% in 2005 compare with 62% in 
1993 [18].
Jafarzadeh et al. found that 81.5% of children had pro-
tective levels of antibody [19] at five years after primary 
hepatitis B immunization while 47.9% of children had 
protective levels of antibody 10 years after primary vac-
cination [20].
In Aghakhani et al. study, protective antibody levels 
were detected in 65% of children one year after vaccina-
tion, which declined significantly over time to 24% in 15 
years after vaccination [21].
Tab. I. distribution of anti-hBs levels according to sex, age and duration after vaccination.
  Anti-HBs ≥ 10 mIU/mL Anti-HBs < 10 mIU/mL Total
    N % N % N
Sex
male 82 78 23 22 105
Female 84 80 21 20 105
Age
< 5 years 58 87 9 13 67
5-10 years 54 81 13 19 67
≥ 10 years 54 71 22 29 76
Duration after vaccination
< 5 years 62 87 9 13 71
5-10 years 54 78 15 22 69
≥ 10 years 52 74 18 26 70
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In Gilca et al. study, 88.2%, 86.4% and 76.7% of cases 
had a titer ≥ 10 IU/L after 5, 10 and 15 years post-vac-
cination [13].
In our study similar to other studies, no differences were 
observed between sex, age and anti-HBs titer following 
the vaccination [8, 21]. 
There are controversies over the long-term persistence 
of post vaccination immunity to hepatitis B. Accord-
ing to meta-analysis, protection which was provided by 
three or four doses of monovalent HB vaccine persists 
for at least two decades in the great majority of im-
munocompetent individuals and 3 doses of HB vac-
cine ensure a good protection against infection for up 
to 20 years [2], while some studies recommend a need 
for booster dose of vaccine in our country  [20,  21]. 
Although a booster dose increases substantially anti-
HBs titers, the clinical relevance of such an increase 
remains unknown. 
In conclusion, the vaccination program has been prov-
en effective in Semnan and immunological protection 
against HBV infection was found in the majority of chil-
dren even more than 10 years after being vaccinated. 
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